Table 4. Pre-dose FEV₁ improvements in studies of ICS/LABA combinations in COPD.

Clinical studies	Pre-dose FEV 1 at baselinea (ml)	Pre-dose FEV 1 versus baselineb (ml)	Pre-dose FEV 1 versus LABAb (ml)	Timepoint considered for FEV 1 comparison
Calverley2 ,c	1,266	120	73	52 weeks
Ferguson4 ,c	950	102	74	52 weeks
Szafranski5 ,d	960	80	80	12 months
Calverley3 ,d	980	N/A	50	12 months
Wedzicha28 ,e	1,052	70	65	48 weeks
Calverley20 ,e	1,140	77	50	48 weeks
Rennard7 ,d	1,020	120	90	12 months
Sharafkhaneh44 ,d	1,000	70	30	12 months
Dransfield6 ,f	N/A	N/A	40	52 weeks

Studies >6 months duration were included. Studies with pre-dose FEV₁ presented were included.

Abbreviations: LABA, long-acting β₂-agonist; N/A, not available.

^aFEV₁ before first dose (baseline).

^bChange in FEV₁ caused by ICS/LABA.

^cStudies conducted with: fluticasone propionate/salmeterol.

^dBudesonide/formoterol fumarate.

^eBeclometasone dipropionate/formoterol fumarate.

^fFluticasone furoate/vilanterol.